Interaction between rifaximin and dietary fibre in patients with diverticular disease

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 7, 2007, Pages 771-779

  D'Inca R ^a,b   Pomerri, F ^b   Vettorato, M G ^b   Dal Pont, E ^b   Di Leo, V ^b   Ferronato, A ^b   Medici, V ^b   Sturniolo, G C ^b  

^a Policlinico   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN; LACTULOSE; RIFAXIMIN;

ADULT; AGED; ARTICLE; BRAN; BREATH ANALYSIS; CLINICAL TRIAL; COLON DIVERTICULOSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIETARY FIBER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FECES ANALYSIS; FEMALE; FOOD DRUG INTERACTION; HEALTH STATUS; HUMAN; INTESTINE FLORA; INTESTINE TRANSIT TIME; MAJOR CLINICAL STUDY; MALE; MICROBIAL DEGRADATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BREATH TESTS; CROSS-OVER STUDIES; DIETARY FIBER; DIVERTICULUM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL TRANSIT; HUMANS; HYDROGEN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RIFAMYCINS;

EID: 33947268835     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03266.x     Document Type: Article

References (31)

1. Jun S, Stolloman H. Epidemiology of diverticular disease. Best Pract Res Clin Gastroenterol 2002; 16: 529-42.
2. Petruzziello L, Iacopini F, Bulajic M, Shah S, Costamagna G. Uncomplicated diverticular disease of the colon. Aliment Pharmacol Ther 2006; 23: 1379-91.
3. Kang JY, Melville D, Maxwell JD. Epidemiology and management of diverticular disease of the colon. Drugs Aging 2004; 21: 211-28.
4. Stollman N, Raskin JB. Diverticular disease of the colon. Lancet 2004; 363: 631-9.
5. Simpson J, Spiller R. Colonic diverticular disease. Clin Evid 2005; 14: 1-2.
6. Marlett JA, McBurney MI, Slavin JL, American Dietetic Association. Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc 2002; 102: 993-1000.
7. Brogribb AJM. Treatment of symptomatic diverticular disease with a high fiber diet. Lancet 1977; 1: 664-6.
8. Ewerth S, Ahlberg J, Holmstrom B, Persson U, Uden R. Influence on symptoms and transit-time of Vi-SiblinR in diverticular disease. Acta Chir Scand Suppl 1980; 500: 49-50.
9. Ornstein MH, Littlewood ER, Baird IM, Fowler J, Cox AG. Are fibre supplements really necessary in diverticular disease of the colon? Br Med J 1981; 282: 1629-30.
10. Weinreich J. Treatment of diverticular disease. Scand J Gastroenterol Suppl 1982; 79: 128-9.
11. Frieri G, Pimpo MT, Scarpignato C. Management of colonic diverticular disease. Digestion 2006; 73 (Suppl. 1): 58-66.
12. Tursi A. Acute diverticulitis of the colon: current medical therapeutic management. Expert Opin Pharmacother 2004; 5: 55-9.
13. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. World J Gastroenterol 2005; 11: 2773-6.
14. Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group. Ital J Gastroenterol 1992; 24: 452-6.
15. Latella G, Pimpo MT, Sottili S, et al. rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003; 18: 55-62.
16. Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 1995; 9: 33-9.
17. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 412-9.
18. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med 2006; 145: 557-63.
19. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101: 326-33.
20. Corazza GR, Strocchi A, Gasbarrini G. Fasting breath hydrogen in celiac disease. Gastroenterology 1987; 93: 53-8.
21. Thompson DG, O'Brien JD, Hardie JM. Influence of the oropharyngeal microflora on the measurement of exhaled breath hydrogen. Gastroenterology 1986; 91: 853-60.
22. 2) response to carbohydrate malabsorption after exercise. J Lab Clin Med 1983; 102: 147-50.
23. Rosenthal A, Solomons NW. Timecourse of cigarette smoke contamination of clinical hydrogen breath-analysis tests. Clin Chem 1983; 29: 1980-1.
24. Kotler DP, Holt PR, Rosensweig NS. Modification of the breath hydrogen test: increased sensitivity for the detection of carbohydrate malabsorption. J Lab Clin Med 1982; 100: 798-805.
25. Badiali D, Corazziari E, Habib FI, et al. Effect of wheat bran in treatment of chronic nonorganic constipation. A double-blind controlled trial. Dig Dis Sci 1995; 40: 349-56.
26. Aldoori W, Ryan-Harshman M. Preventing diverticular disease. Review of recent evidence on high-fibre diets. Can Fam Physician 2002; 48: 1632-7.
27. Colecchia A, Sandri L, Capodicasa S, et al. Diverticular disease of the colon: new perspectives in symptom development and treatment. World J Gastroenterol 2003; 9: 1385-9.
28. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut 2002; 51 (Suppl. 1): 141-4.
29. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-9.
30. Ventrucci M, Ferrieri A, Bergami R, et al. Evaluation of the effect of rifaximin in colon diverticular disease by means of lactulose hydrogen breath test. Curr Med Res Opin 1994; 13: 202-6.
31. Kurpad AV, Shetty PS. Effects of antimicrobial therapy on fecal bulking. Gut 1986; 27: 55-8.